According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

INR:9523. newcastle horse racing tips today Is the Cold Winter of Private Medical Care Coming? In-depth Analysis of ...

Orphan Medicines, led by the gene therapy Zolgensma and the Cystic Fibrosis treatment Trikafta were the most successful launches according to IQVIA list price sales data in Europe in 2020 (figure 2).

Published first on TheFly – the ul The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial The crisis of purchasing imported consumables in bulk in 10 provinc ...

Johnson & Johnson terminates global Phase III clinical trial of Stelara for the treatment of systemic lupus erythematosus Trikafta, a triple combination therapy for CF in patients with specific gene ...

Robin - Sherwin Marauders Kanghong Pharmaceuticals Vice President, Chief Financial Officer and Secretary Zhong Jianjun received a regulatory letter for "illegal purchase of stocks" Vertex's triple ...